Huberman noted that while first-generation weight-loss drugs curbed users’ appetites, they frequently plunged them into massive, rapid caloric deficits.<\/p>\n
‘NEXT OZEMPIC’ AIMS TO DELIVER 30% WEIGHT LOSS WITH FEWER SIDE EFFECTS<\/strong><\/a><\/p>\n Without aggressive resistance training<\/a>, a high percentage of that lost weight came directly from lean muscle. “People would lose a ton of weight, but they would also lose muscle mass,” Huberman told Paltrow.<\/p>\n In clinical trials, retatrutide is administered as a once-weekly subcutaneous injection. (iStock)<\/p>\n That is where retatrutide comes in, he said. Unlike older single- or dual-action medications, retatrutide is a triple agonist<\/a>.<\/p>\n That means it activates the body’s receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon \u2013 three hormones involved in regulating blood sugar, appetite and metabolism.<\/p>\n WEIGHT-LOSS EXPERTS PREDICT 5 MAJOR TREATMENT CHANGES LIKELY TO EMERGE IN 2026<\/strong><\/a><\/p>\n “Retatrutide is a more mild agonist of GLP-1,” said Huberman. “It also increases glucagon and … GIP. So, it hits three different pathways, each a bit more subtly.”<\/p>\n In clinical trials<\/a>, retatrutide is administered as a once-weekly subcutaneous injection.<\/p>\n Without aggressive resistance training, a high percentage of lost weight can come directly from lean muscle mass, said Andrew Huberman. (iStock)<\/p>\n Because of its balanced, multi-receptor approach, Huberman said the drug has a “lower side effect profile” while still allowing people to lose up to a third of their body weight “across a year or so.”<\/p>\n NEW OZEMPIC-ALTERNATIVE DIABETES PILL BURNS FAT WITHOUT MUSCLE LOSS, STUDY SUGGESTS<\/strong><\/a><\/p>\n Most importantly for fitness and longevity<\/a> advocates, the doctor pointed out that retatrutide seems to have “some muscle sparing effect.”<\/p>\n Because the drug is still moving through official pipelines, a massive gray market of compounding pharmacies and online peptide suppliers has cropped up to meet the growing demand.<\/p>\n Retatrutide is an investigational molecule that is legally available only to participants in Lilly\u2019s clinical trials, according to Lilly\u2019s website, and the company is currently “evaluating its safety and efficacy” in these clinical studies. (iStock)<\/p>\n Huberman issued a strict warning regarding these unregulated online sources, noting that these options “can say 99% purity, but that 1% means there could be some LPS,” referring to lipopolysaccharides, a type of bacterial toxin<\/a>.<\/p>\n CLICK HERE FOR MORE HEALTH STORIES<\/strong><\/a><\/p>\n “LPS will cause inflammation,” he cautioned. “One injection isn’t gonna do it, but multiple injections over time, I could see where that could become problematic.”<\/p>\n CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER<\/strong><\/a><\/p>\n Paltrow echoed the safety concerns, comparing the current “wild-west” peptide craze<\/a> to the landscape of supplements in the 90s, “where there’s really no third-party testing and it’s kind of word of mouth.”<\/p>\n “Multiple injections over time, I could see where that could become problematic.”<\/p>\n<\/blockquote>\n Both agreed that anyone exploring these therapies should avoid unverified online sources and prioritize working with a medical doctor<\/a>.<\/p>\n TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ<\/strong><\/a><\/p>\n Retatrutide is an investigational molecule that is legally available only to participants in Lilly\u2019s clinical trials, according to the manufacturer’s website. The company is currently “evaluating its safety and efficacy.”<\/p>\n![\"A](\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2026\/05\/doctor-peptide-vial-fox-news-001.jpeg\")
<\/p>\n![\"Female](\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2026\/05\/measure-man-belly-fat.jpg\")
<\/p>\n![\"Woman](\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2026\/05\/woman-peptide-injection-fox-news-001.jpeg\")
<\/p>\n\n